Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 6/2010

01-12-2010 | Editorial

A French approach to cost-effectiveness analysis?

Author: Gérard de Pouvourville

Published in: The European Journal of Health Economics | Issue 6/2010

Login to get access

Excerpt

France is still considered as a paradigmatic country in terms of its refusal to consider health economic assessments when deciding on access to reimbursement and pricing of drugs and medical devices. In a recent editorial of this journal [1], Claude Le Pen has argued that this may reflect a “continental” view of health economics and in particular a specific philosophical conception of illness, health and medicine, which resists the idea that “health and illness differ only in quantitative states” and thus “cannot be plotted in the same space”. …
Footnotes
1
Code de la Sécurité Sociale. Livre 1, Titre 6, Chapitre 3.
 
2
Author’s translation.
 
3
Haute Autorité de Santé.
 
4
HAS. Efficacité et efficience des hypolipémaints: une analyse centrée sur les statines, July 22, 2010. http://​www.​has-sante.​fr/​portail/​jcms/​c_​968816/​efficacite-et-efficience-des-hypolipemiants-une-analyse-centree-sur-les-statines.
 
Literature
1.
Le Pen, C.: Is there a «continental» view of health economics evaluation? Eur. J. Health Econ. 10, 121–123 (2009)CrossRef
2.
Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, E., et al.: Comparison of the efficacy and safety of rosuvastatin versusatorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92(2), 152–160 (2003)CrossRef
3.
Law, M., Wald, N.J., Rudnicka, A.R.: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 326, 1423 (2003)CrossRef
Metadata
Title
A French approach to cost-effectiveness analysis?
Author
Gérard de Pouvourville
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 6/2010
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0284-9

Other articles of this Issue 6/2010

The European Journal of Health Economics 6/2010 Go to the issue

Original Paper

The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands

Original Paper

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

Original Paper

Adolescents alcohol-use and economic conditions: a multilevel analysis of data from a period with big economic changes

Original Paper

The effect of health care expenditure on sickness absence

Original Paper

On the welfare theoretic foundation of CEA: comment

Original Paper

Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply